Diversify Wealth Management LLC Takes Position in Grifols, S.A. $GRFS

Diversify Wealth Management LLC bought a new position in Grifols, S.A. (NASDAQ:GRFS) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 122,588 shares of the biotechnology company’s stock, valued at approximately $1,156,000.

A number of other hedge funds have also recently made changes to their positions in the company. Versant Capital Management Inc raised its position in shares of Grifols by 39.5% in the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,584 shares in the last quarter. Peterson Wealth Services increased its stake in Grifols by 385.8% in the 3rd quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 5,787 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 4,604 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Grifols by 109.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 4,518 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in shares of Grifols during the second quarter worth about $95,000.

Analysts Set New Price Targets

GRFS has been the topic of a number of recent analyst reports. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. JPMorgan Chase & Co. dropped their price objective on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a report on Monday, December 8th. Finally, Wall Street Zen cut Grifols from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Four research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Grifols Stock Up 1.6%

Shares of GRFS opened at $9.10 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.93 and a current ratio of 2.48. Grifols, S.A. has a fifty-two week low of $6.19 and a fifty-two week high of $11.14. The firm has a 50 day moving average price of $9.22 and a 200-day moving average price of $9.35.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.